<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753623</url>
  </required_header>
  <id_info>
    <org_study_id>2008P-000988</org_study_id>
    <nct_id>NCT00753623</nct_id>
  </id_info>
  <brief_title>Clinical Management of Neuropathic Pain With Ramelteon</brief_title>
  <official_title>Clinical Management of Neuropathic Pain With Ramelteon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal is to conduct a double-blinded, randomized, placebo-controlled, crossover
      clinical study to examine the hypothesis that ramelteon would reduce pain score and improve
      functional status in subjects with neuropathic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuropathic pain is a chronic pain condition resulting from injury to the peripheral and/or
      central nervous system. Despite extensive research over the last several decades, neuropathic
      pain remains poorly managed due to the lack of effective pharmacological tools. To date,
      little has been known regarding the effect of melatonin and its analogues on clinical
      neuropathic pain. We propose to conduct a randomized, placebo-controlled, double-blinded, and
      crossover clinical trial to examine the effect of ramelteon [a melatonin (MT) 1/ MT2 receptor
      agonist] on neuropathic pain. We hypothesize that ramelteon would reduce pain score and
      improve functional status in subjects with neuropathic pain.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment did not accrue as expected.
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Visual Analog Scale (VAS) for Pain (0-10) Between Treatments</measure>
    <time_frame>VAS score at baseline and after the treatment period</time_frame>
    <description>Subjects were asked to rate their pain the VAS with 0 being no pain and 10 being the worst pain they can imagine. The VAS scores were compared between the baseline and after a period of treatment. A negative number indicates an improvement in pain from baseline score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Ramelteon first, placebo second</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.
The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, ramelteon second</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.
The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>ramelteon (8 mg)</description>
    <arm_group_label>Ramelteon first, placebo second</arm_group_label>
    <arm_group_label>Placebo first, ramelteon second</arm_group_label>
    <other_name>Rozerem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.</description>
    <arm_group_label>Ramelteon first, placebo second</arm_group_label>
    <arm_group_label>Placebo first, ramelteon second</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject will be between ages 18 to 65 years.

          2. Subject has not been on ramelteon for at least one month.

          3. Subject agrees to make no change in his/her current pain medications during the entire
             study period (5 weeks). This requirement will ensure that valid comparisons of primary
             and secondary measures can be made before and after the study.

          4. Subject has a VAS pain score of 5 or above at the beginning of the study.

          5. Subject has had a neuropathic pain condition as listed above for at least three
             months. This requirement is to avoid clinical uncertainty from an unstable pain
             condition and to minimize the study variation.

          6. Female subjects of childbearing potential must have a negative urine pregnancy test at
             the initial visit.

        Exclusion Criteria:

          1. Subject has moderate to severe liver impairment.

          2. Subject has Liver Function Tests (LFT's) &gt;1.5X normal.

          3. Subject has a history of renal impairment.

          4. Subject has moderate or severe cardiac or pulmonary disease including a base line
             oxygen saturation of less than 95% on room air or any requirement for supplemental
             oxygen.

          5. Subject has a history of glaucoma.

          6. Subject has obstructive sleep apnea.

          7. Subject is taking medications for sleep disorders including insomnia.

          8. Subject has a major psychiatric disorder (major depression requiring a recent
             hospitalization within three months prior to the study; bipolar disorder;
             schizophrenia; psychotic disorders; substance abuse).

          9. Subject has a history of dementia or delirium.

         10. Subject has a history of falls.

         11. Subject is pregnant or lactating.

         12. Subject is using an illicit drug detected by a screening test.

         13. Subject is currently taking Fluvoxamine.

         14. Subject has been taking Ketoconazole in the past two weeks.

         15. Subject has known hypersensitivity to ramelteon.

         16. Subject has pending litigation related to his/her neuropathic pain condition.

         17. Subject has Concurrent participation in other research drug trials or other study
             participation within 30 days of enrollment in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianren Mao, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massgeneral.org/painresearch/</url>
    <description>MGH Center for Translational Pain Research</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <results_first_submitted>November 1, 2013</results_first_submitted>
  <results_first_submitted_qc>June 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2014</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jianren Mao, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Neuropathic pain</keyword>
  <keyword>Pain scores</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited in person at the MGH Center for Pain or by advertisement throughout MGH and the local community.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Phase I; Ramelteon Phase II</title>
          <description>In a crossover design, a subject was first assigned to the placebo and then switched over to the ramelteon.
Ramelteon : ramelteon (8 mg)</description>
        </group>
        <group group_id="P2">
          <title>Ramelton Phase I; Placebo Phase II</title>
          <description>In a crossover design, a subject was first assigned to the ramelteon and then switched over to the placebo.
Ramelteon : ramelteon (8 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Phase I; Ramelteon Phase II</title>
          <description>In a crossover design, a subject was first assigned to the placebo and then switched over to the ramelteon.
Ramelteon : ramelteon (8 mg)</description>
        </group>
        <group group_id="B2">
          <title>Ramelton Phase I; Placebo Phase II</title>
          <description>In a crossover design, a subject was first assigned to the ramelteon and then switched over to the placebo.
Ramelteon : ramelteon (8 mg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Visual Analog Scale (VAS) for Pain (0-10) Between Treatments</title>
        <description>Subjects were asked to rate their pain the VAS with 0 being no pain and 10 being the worst pain they can imagine. The VAS scores were compared between the baseline and after a period of treatment. A negative number indicates an improvement in pain from baseline score.</description>
        <time_frame>VAS score at baseline and after the treatment period</time_frame>
        <population>Only 15 subjects completed both treatment phases so we only included these subjects in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Participants who received Ramelteon 8 mg during the first or last 2 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo medication during the first or last 2 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Visual Analog Scale (VAS) for Pain (0-10) Between Treatments</title>
          <description>Subjects were asked to rate their pain the VAS with 0 being no pain and 10 being the worst pain they can imagine. The VAS scores were compared between the baseline and after a period of treatment. A negative number indicates an improvement in pain from baseline score.</description>
          <population>Only 15 subjects completed both treatment phases so we only included these subjects in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.4"/>
                    <measurement group_id="O2" value="-1.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two weeks for each intervention and a 1 week period of no intervention in between phases.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ramelteon</title>
          <description>Participants who received Ramelteon 8 mg during the first or last 2 weeks of the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants who received placebo medication during the first or last 2 weeks of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Problems with recruitment and termination of the study consequently resulted in uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jianren Mao</name_or_title>
      <organization>MGH Center for Translational Pain Research</organization>
      <phone>617-724-6102</phone>
      <email>mghpainresearch@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

